PCM
BLTE

Prelude Capital Management’s Belite Bio BLTE Stock Holding History

Prelude Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,119
Closed -$499K – 1233
2025
Q4 		$499K Buy
+3,119
New +$369K 0.04% 539

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's BLTE Position: Q1 2026 in Review

Prelude Capital Management sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 3,119 shares — an estimated $499K sold.

Prelude Capital Management first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $499K in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Prelude Capital Management reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 3,119 Belite Bio shares in Q1 2026, an estimated $499K.
  • Prelude Capital Management first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
  • Prelude Capital Management's Belite Bio position peaked at $499K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.